This finding further confirms the potential clinical utility of plasma NfL as a marker of drug effect, provides that the tested novel therapeutics will result in a significant reduction of NfL levels, as recently proved for nusinersen in pediatric spinal muscular atrophy (Darras et al., 2019; Johannsen et al., 2021). The gene discussed is NEFL; the disease is proximal spinal muscular atrophy.